StockIQpro
NASDAQ:LTRN

Lantern Pharma Inc.

Track all markets on TradingView
Track all markets on TradingView

Lantern Pharma Inc. reported net income of −$17.1M in fiscal 2025. Free cash flow was −$15.7M, and the diluted share count rose 1.3%.Summary generated from Lantern Pharma Inc.'s SEC filings. Latest annual report filed Mar 30, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−123.5%
Debt / equityn/a
Free cash flow−$15.7M
FCF marginn/a
Share count change+1.3%

Financials

Fiscal years, $M
Item20212022202320242025
Revenuen/an/an/an/an/a
Operating income−13−14−18−22−18
Net income−12−14−16−21−17
Free cash flow−11−13−14−18−16

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations